Ray Dalio Novo Cure LTD Transaction History
Bridgewater Associates, LP
- $17.3 Billion
- Q3 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Novo Cure LTD stock. As of the latest transaction made, Bridgewater Associates, LP holds 39,383 shares of NVCR stock, worth $876,271. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,383
Previous 81,281
51.55%
Holding current value
$876,271
Previous $1.39 Million
55.82%
% of portfolio
0.0%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding NVCR
# of Institutions
266Shares Held
73.8MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$270 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$264 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$176 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$95.9 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.81MShares$62.4 Million0.03% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.34B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...